Citations

Mayo Clinic

Showing 10 of 108551 citations.

MYC Is a Crucial Mediator of TGFβ-Induced Invasion in Basal Breast Cancer
Cichon, Magdalena A., Moruzzi, Megan E., Shqau, Tiziana A., Miller, Erin , Mehner, Christine , Ethier, Stephen P. , Copland, John A. , Radisky, Evette S. , Radisky, Derek C. , Radisky, Evette S

Cancer Research | April 14, 2016 | Volume: 76 | Issue: 12 | Pages: 3520-3530

10.1158/0008-5472.can-15-3465 | PMID 27197167 Get It

Abstract Basal subtype breast cancers have a particularly poor prognosis, with high invasiveness and resistance to most targeted therapies. TGFβ and MYC drive central features of basal breast cancer: TGFβ is an autocrine and paracrine signaling factor that drives cell invasion and metastasis, and MYC is a central regulator of cellular proliferation that is upregulated in many cancer types. We show here that genetic or pharmacologic inhibition of MYC in MCF10A basal breast cells results in increased sensitivity to TGFβ-stimulated invasion and metastasis and also show that this signaling loop is dependent on activation of SRC. Analysis of human breast cancer datasets and additional experiments with breast cancer cell lines further suggest the relevance of this signaling loop in basal, but not luminal, breast cancers. Our results imply precaution should be taken when utilizing therapeutic inhibitors of MYC with basal breast cancer patients as this could lead to increased metastasis; however, simultaneous pharmacologic inhibition of SRC and MYC for these patients could facilitate the antiproliferative effects of MYC inhibition while blocking the consequent promotion of metastasis. Cancer Res; 76(12); 3520–30. ©2016 AACR.
Strain Response of the Anterior Cruciate Ligament to Uniplanar and Multiplanar Loads During Simulated Landings
Kiapour, Ata M. , Demetropoulos, Constantine K. , Kiapour, Ali , Quatman, Carmen E. , Wordeman, Samuel C., Hewett, Timothy E. , Goel, Vijay K.

The American Journal of Sports Medicine | April 14, 2016 | Volume: 44 | Issue: 8 | Pages: 2087-2096

10.1177/0363546516640499 | PMID 27159285 Get It

Background: Despite basic characterization of the loading factors that strain the anterior cruciate ligament (ACL), the interrelationship(s) and additive nature of these loads that occur during noncontact ACL injuries remain incompletely characterized. Hypothesis: In the presence of an impulsive axial compression, simulating vertical ground-reaction force during landing (1) both knee abduction and internal tibial rotation moments would result in increased peak ACL strain, and (2) a combined multiplanar loading condition, including both knee abduction and internal tibial rotation moments, would increase the peak ACL strain to levels greater than those under uniplanar loading modes alone. Study Design: Controlled laboratory study. Methods: A cadaveric model of landing was used to simulate dynamic landings during a jump in 17 cadaveric lower extremities (age, 45 ± 7 years; 9 female and 8 male). Peak ACL strain was measured in situ and characterized under impulsive axial compression and simulated muscle forces (baseline) followed by addition of anterior tibial shear, knee abduction, and internal tibial rotation loads in both uni- and multiplanar modes, simulating a broad range of landing conditions. The associations between knee rotational kinematics and peak ACL strain levels were further investigated to determine the potential noncontact injury mechanism. Results: Externally applied loads, under both uni- and multiplanar conditions, resulted in consistent increases in peak ACL strain compared with the baseline during simulated landings (by up to 3.5-fold; P ≤ .032). Combined multiplanar loading resulted in the greatest increases in peak ACL strain ( P < .001). Degrees of knee abduction rotation ( R 2 = 0.45; β = 0.42) and internal tibial rotation ( R 2 = 0.32; β = 0.23) were both significantly correlated with peak ACL strain ( P < .001). However, changes in knee abduction rotation had a significantly greater effect size on peak ACL strain levels than did internal tibial rotation (by ~2-fold; P < .001). Conclusion: In the presence of impulsive axial compression, the combination of anterior tibial shear force, knee abduction, and internal tibial rotation moments significantly increases ACL strain, which could result in ACL failure. These findings support multiplanar knee valgus collapse as one the primary mechanisms of noncontact ACL injuries during landing. Clinical Relevance: Intervention programs that address multiple planes of loading may decrease the risk of ACL injury and the devastating consequences of posttraumatic knee osteoarthritis.
Sedation shared decision-making in ambulatory venous access device placement: Effects on patient choice, satisfaction and recovery time
Chittle, Melissa D , Öklü, Rahmi , Pino, Richard M. , He, Ping , Sheridan, Robert M., Martino, Joanne, Hirsch, Joshua A , Martino, Joanne, Oklu, Rahmi

Vascular Medicine | April 13, 2016 | Volume: 21 | Issue: 4 | Pages: 355-360

10.1177/1358863x16643602 | PMID 27076197 Get It

This study was undertaken to determine the impact of shared decision-making when selecting a sedation option, from no sedation (local anesthetic), minimal sedation (anxiolysis with a benzodiazepine) or moderate sedation (benzodiazepine and opiate), for venous access device placement (port-a-cath and tunneled catheters) on patient choice, satisfaction and recovery time. This is an IRB-approved, HIPPA-compliant, retrospective study of 198 patients (18–85 years old, 60% female) presenting to an ambulatory vascular interventional radiology department for venous access device placement between 22 October 2014 and 7 October 2015. Patients were educated about sedation options and given the choice of undergoing the procedure with no sedation (local anesthetic only), or minimal or moderate sedation. Satisfaction was assessed through three survey questions. No sedation was selected by 53/198 (27%), minimal sedation by 71/198 (36%) and moderate sedation by 74/198 (37%). All subjects would recommend the option to another patient and valued the opportunity to select a sedation option. Post-procedure recovery time differences were statistically significant ( p<0.0001) with median recovery times of 0 minutes for no sedation, 38 minutes for minimal sedation and 64 minutes for moderate sedation. In conclusion, patient sedation preference for venous access device placement is variable, signifying there is a role for shared decision-making as it empowers the patient to select the option most aligned with his or her goals. The procedure is well-tolerated, associated with high satisfaction, and the impact on departmental flow is notable because patients choosing no or minimal sedation results in a decreased post-procedure recovery time burden.
Association of a Family History of Coronary Heart Disease With Initiation of Statin Therapy in Individuals at Intermediate Risk
Safarova, Maya , Bailey, Kent R. , Safarova, Maya S, Kullo, Iftikhar J.

JAMA Cardiology | April 13, 2016 | Volume: 1 | Issue: 3 | Pages: 364

10.1001/jamacardio.2016.0227 | PMID 27438122 Get It

We Restrict CRRT to Only the Most Hemodynamically Unstable Patients
Mehta, Ravindra L. , Kashani, Kianoush , Mehta, Ravindra L

Seminars in Dialysis | April 13, 2016 | Volume: 29 | Issue: 4 | Pages: 268-271

10.1111/sdi.12507 | PMID 27074128 Get It

AbstractFrom the initial version of an extended renal replacement therapy, the initiative to provide safer, more efficient means for detoxification and volume removal in comparison with intermittent renal replacement therapies (IRRT) has been evaluated. As a result, the Kidney Disease Improving Global Outcomes guidelines for acute kidney injury recommend the preferential use of continuous renal replacement therapy (CRRT) in patients who are hemodynamically unstable or who suffer from intracranial hypertension. The choice of dialysis modality is also influenced by other factors including clinical expertise, and the availability of each treatment option in individual medical centers. In the scientific community, there is an ongoing debate regarding the choice of dialysis modality. On one side, the inability of recent studies to demonstrate any mortality or renal recovery benefit for CRRT, the need for patient immobilization, and prohibitive additional costs impede widespread adoption of the method.On the other side, the physiological advantages of CRRT in detoxification and volume removal and the identified flaws related to the comparative literature regarding CRRT and IRRT fuel this debate. Fluid overload is a recognized and yet clinically underappreciated factor that increases morbidity and mortality in the intensive care unit (ICU). Continuous renal replacement therapy has a distinct advantage over IRRT in achieving euvolemia and thus the potential for improving outcomes in all patients in the ICU setting in which extensive fluid administration is often obligatory. With this in mind, perhaps CRRT should not be restricted to only those patients in whom their hemodynamic status requires it. This article reviews the current literature and the myths that may influence the selection of one mode of therapy over the other among patients requiring renal replacement therapy in the ICU.
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Rutgeerts, Paul, Sandborn, William J. , Danese, Silvio , D’Haens, Geert , Loftus, Edward V. , Sankoh, Serap, Fox, Irving H., Parikh, Asit, Milch, Catherine , Abhyankar, Brihad, Feagan, Brian G. , Colombel, Jean‐Frédéric , Sands, Bruce E , Panaccione, Remo , Loftus, Edward V , Danese, Silvio

Gut | April 13, 2016 | Volume: 66 | Issue: 5 | Pages: 839-851

10.1136/gutjnl-2015-311079 | PMID 26893500 Get It

Objective Vedolizumab is a gut-selective antibody to α 4 β 7 integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We report an integrated summary of the safety of vedolizumab. Design Safety data (May 2009–June 2013) from six trials of vedolizumab were integrated. Adverse events were evaluated in patients who received ≥1 dose of vedolizumab or placebo and were reported as exposure-adjusted incidence rates as the number of patients experiencing the event per 100 person-years (PYs) of exposure. Predictors of serious infection were assessed using a Cox proportional hazards model. Results In total, 2830 patients had 4811 PYs of vedolizumab exposure (median exposure range, 1–1977 days). No increased risk of any infection or serious infection was associated with vedolizumab exposure. Serious clostridial infections, sepsis and tuberculosis were reported infrequently (≤0.6% of patients). No cases of progressive multifocal leucoencephalopathy were observed. Independent risk factors for serious infection in UC were prior failure of a tumour necrosis factor α antagonist (HR, 1.99; 95% CIs 1.16 to 3.42; p=0.0122) and narcotic analgesic use (HR, 2.68; 95% CI 1.57 to 4.58; p=0.0003), and in CD were younger age (HR, 0.97; 95% CI 0.95 to 0.98; p<0.0001), corticosteroid (HR, 1.88; 95% CI 1.35 to 2.63; p=0.0002) or narcotic analgesic use (HR, 2.72; 95% CI 1.90 to 3.89; p<0.0001). Investigator-defined infusion-related reactions were reported for ≤5% of patients in each study. Eighteen vedolizumab-exposed patients (<1%) were diagnosed with a malignancy. Conclusions Vedolizumab has a favourable safety profile with low incidence rates of serious infections, infusion-related reactions and malignancies over an extended treatment period. Trial registration number NCT01177228, NCT00619489 , NCT00783718 , NCT00783692 , NCT01224171 , NCT00790933 .
Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay
Levitsky, Konstantin, Parlati, Francesco , Bennett, Mark K. , Arastu‐Kapur, Shirin, Kellerman, Lois, Woo, Tina F., Papadopoulos, Kyriakos P. , Niesvizky, Rubén, Badros, Ashraf , Vij, Ravi , Wang, Michael , Ahmann, Gregory , Kirk, Christopher J., Ahmann, Gregory J, Lee, Sang Hyuck , Wong, Alvin , Jagannath, Sundar , Siegel, David S.

British Journal of Haematology | April 13, 2016 | Volume: 173 | Issue: 6 | Pages: 884-895

10.1111/bjh.14014 | PMID 27071340 Get It

SummaryWhile proteasome inhibition is a validated therapeutic approach for multiple myeloma (MM), inhibition of individual constitutive proteasome (c20S) and immunoproteasome (i20S) subunits has not been fully explored owing to a lack of effective tools. We utilized the novel proteasome constitutive/immunoproteasome subunit enzyme‐linked immunosorbent (ProCISE) assay to quantify proteasome subunit occupancy in samples from five phase I/II and II trials before and after treatment with the proteasome inhibitor carfilzomib. Following the first carfilzomib dose (15–56 mg/m2), dose‐dependent inhibition of c20S and i20S chymotrypsin‐like active sites was observed [whole blood: ≥67%; peripheral blood mononuclear cells (PBMCs): ≥75%]. A similar inhibition profile was observed in bone marrow–derived CD138+ tumour cells. Carfilzomib‐induced proteasome inhibition was durable, with minimal recovery in PBMCs after 24 h but near‐complete recovery between cycles. Importantly, the ProCISE assay can be used to quantify occupancy of individual c20S and i20S subunits. We observed a relationship between MM patient response (n = 29), carfilzomib dose and occupancy of multiple i20S subunits, where greater occupancy was associated with an increased likelihood of achieving a clinical response at higher doses. ProCISE represents a new tool for measuring proteasome inhibitor activity in clinical trials and relating drug action to patient outcomes.
Correlated gene expression encoding serotonin (5‐HT) receptor 4 and 5‐HT transporter in proximal colonic segments of mice across different colonization states and sexes
Reigstad, Christopher S., Szurszewski, Joseph H., Sonnenburg, Justin L. , Farrugia, Gianrico , Kashyap, Purna , Linden, David R.

Neurogastroenterology & Motility | April 13, 2016 | Volume: 28 | Issue: 9 | Pages: 1443-1448

10.1111/nmo.12840 | PMID 27072889 Get It

AbstractThe production and handling of serotonin (5‐HT) is an important determinant of colonic motility and has been reported to be altered in gastrointestinal (GI) disorders such as irritable bowel syndrome (IBS). Recent studies suggest that the intestinal microbiota and sex of the host can influence expression of genes involved in 5‐HT biosynthesis and signaling. While expression of genes in serotonergic pathways has been shown to be variable, it remains unclear whether genes within this pathway are coregulated. As a first step in that direction, we investigated potential correlations in relative mRNA expression of serotonergic genes, in the proximal colon isolated from male and female mice in different states of microbial association: germ‐free (GF), humanized (ex‐germ‐free colonized with human gut microbiota, HM), and conventionally raised (CR) mice. Among the 10 pairwise comparisons conducted between five serotonergic transcripts, Tph1, Chga, Maoa, Slc6a4, and Htr4, we found a strong, positive correlation between colonic expression of Slc6a4 and Htr4 across different colonization states and sexes. We also identified a positive correlation between the expression of Tph1 and Chga; however, there were no correlations observed between any other tested pair of 5‐HT‐related transcripts. These data suggest that correlated expression of Slc6a4 and Htr4 likely involves coregulation of genes located on different chromosomes which modulate serotonergic activity in the gut. Further work will need to be done to understand the pathways and cell types responsible for this correlated expression, given the important role of 5‐HT in gastrointestinal physiology.
Synthesis of a peptide-universal nucleotide antigen: towards next-generation antibodies to detect topoisomerase I-DNA covalent complexes
Perkins, Angela L., Peterson, Kevin L. , Beito, Thomas G., Flatten, Karen S., Kaufmann, Scott H. , Harki, Daniel A. , Kaufmann, Scott H , Harki, Daniel A

Organic & Biomolecular Chemistry | April 13, 2016 | Volume: 14 | Issue: 17 | Pages: 4103-4109

10.1039/c5ob02049b | PMID 27113574 Get It

A peptide-universal nucleotide conjugate that mimics the topoisomerase I-DNA covalent complex was synthesized and then utilized to raise monoclonal antibodies.